<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541216</url>
  </required_header>
  <id_info>
    <org_study_id>ephedrine-hmo-ctil</org_study_id>
    <nct_id>NCT00541216</nct_id>
  </id_info>
  <brief_title>Ephedrine for the Treatment of Congenital Myasthenia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous research has demonstrated possible efficacy of Ephedrine in the treatment of&#xD;
      congenital myasthenia caused by end-plate acetylcholinesterase deficiency.&#xD;
&#xD;
      The aim of the current study is to test the hypothesis that Ephedrine may be beneficial to&#xD;
      these patients.&#xD;
&#xD;
      To test this hypothesis we will perform a double blind, placebo-controlled, crossover study&#xD;
      clinical efficacy and safety study.&#xD;
&#xD;
      Drug na√Øve patients who agree to participate will be randomized to two groups. Each group&#xD;
      will be treated in a blinded manner for 5 weeks with either placebo or Ephedrine HCl in an&#xD;
      escalating dose up to 100 mg per day divided in two doses. After five weeks the groups will&#xD;
      cross over and continue treatment or placebo for a further five weeks.&#xD;
&#xD;
      Evaluations of strength and fatiguability will be done at baseline, at the end of each five&#xD;
      week period and after a further two weeks.&#xD;
&#xD;
      Safety will be assessed weekly by the investigators using interview and physical examination.&#xD;
&#xD;
      Outcome measures will include Barthel index, Quality of life questionnaire, Timed up and go,&#xD;
      spirometry, timed elevation of limbs, and force measurements.&#xD;
&#xD;
      All patients will report to the clinic as per study schedule (See Appendix A). Specifically,&#xD;
      the 12 clinic visits will include: baseline (1), safety and efficacy assessments(10) and&#xD;
      closeout (1).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2007</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>strength and fatiguability: walking, straight arm raising, spirometry.</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Myasthenic Syndromes, Congenital</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients , with congenital myasthenia, belonging to a previously&#xD;
             reported kindred diagnosed with COLQ deficiency.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to Ephedrine or any inactive component.&#xD;
&#xD;
          -  Significant abnormalities in screening Cardiovascular parameters (blood pressure,&#xD;
             pulse).&#xD;
&#xD;
          -  Surgery within 6 weeks of screening.&#xD;
&#xD;
          -  Concurrent use of any other medication except steroids.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Thyrotoxicosis.&#xD;
&#xD;
          -  Co-morbid conditions or other neurological disorders that would confound assessment of&#xD;
             clinical parameters.&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days of study start.&#xD;
&#xD;
          -  Patients who are non-cooperative or parents/ legal guardians who are unwilling to sign&#xD;
             consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Simon Edvardson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Jerusalem, Israel</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 7, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <last_update_submitted>October 9, 2007</last_update_submitted>
  <last_update_submitted_qc>October 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2007</last_update_posted>
  <keyword>congenital myasthenia</keyword>
  <keyword>ephedrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
    <mesh_term>Myasthenic Syndromes, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

